THYROCARE
Thyrocare Technologies Limited
Healthcare · Diagnostics & Research
Market price data is delayed by at least 15 minutes. Not for trading or investment decisions.
Fundamentals
Current Price
₹393.4
P/B Ratio
11.71
52W High
₹536.67
52W Low
₹226.05
Dividend Yield
2.39%
Profit Margin
17.35%
ROE
—
Debt / Equity
0.05
Sector
Healthcare
Industry
Diagnostics & Research
Peer Comparison same NSE industry · top 10 by 1M return
Hospital Healthcare Servicesas of 8 Apr 2026 close
| Symbol | Company | Price | P/B | RSI | 1M Ret | ROE | D/E |
|---|---|---|---|---|---|---|---|
| THYROCAREyou | Thyrocare Technologies Limit | ₹390.45 | 11.62 | 62.0 | +4.1% | — | 0.05 |
| MEDIASSIST | Medi Assist Healthcare Servi | ₹362.05 | 4.39 | 65.6 | +20.8% | — | 0.52 |
| LAXMIDENTL | Laxmi Dental Limited | ₹192.12 | 4.50 | 62.6 | +10.5% | — | 0.04 |
| GAUDIUMIVF | Gaudium IVF and Women Health | ₹79.22 | 10.51 | 48.2 | +7.7% | — | — |
| RAINBOW | Rainbow Childrens Medicare L | ₹1,271.1 | 8.50 | 77.4 | +7.5% | — | 0.53 |
| SHALBY | Shalby Limited | ₹152.21 | 1.65 | 58.9 | +5.9% | — | 0.53 |
| YATHARTH | Yatharth Hospital & Trauma C | ₹702.45 | 4.01 | 61.7 | +5.7% | — | 0.02 |
| FLAIR | Flair Writing Industries Lim | ₹307.85 | 3.01 | 55.7 | +2.9% | — | 0.05 |
| METROPOLIS | Metropolis Healthcare Limite | ₹456 | 6.59 | 48.3 | +2.3% | — | 0.14 |
| PARKHOSPS | Park Medi World Limited | ₹206.16 | 6.60 | 61.3 | +2.2% | — | 0.58 |
| KRSNAA | Krsnaa Diagnostics Limited | ₹599.1 | 2.11 | 49.9 | +1.9% | — | 0.31 |
Price Chart
Quarterly Results Last 4 quarters
| Metric | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|
| Revenue | ₹195.5 Cr | — | ₹193.0 Cr | ₹187.2 Cr |
| Gross Profit | ₹148.3 Cr | — | ₹137.4 Cr | ₹137.6 Cr |
| Operating Income | ₹36.2 Cr | — | ₹46.4 Cr | ₹44.6 Cr |
| Net Income | ₹29.0 Cr | — | ₹39.0 Cr | ₹21.6 Cr |
Values in INR Crore. Source: yfinance / NSE filings.
SWOT Analysis AI · news + fundamentals
SWOT not available.
Recent News Sentiment
No recent news for this stock.
Data sourced from yfinance and public NSE filings. Not investment advice.